News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ambit Biosciences to Present at the19th Annual Future Leaders in the Biotech Industry Conference


4/16/2012 10:05:25 AM

SAN DIEGO, April 16, 2012 /PRNewswire/ -- Ambit Biosciences today announced that the company is scheduled to present at the 19th Annual Future Leaders in the Biotech Industry Conference at 8:30 a.m. EDT on Friday, April 20, 2012, at the Millennium Broadway Hotel in New York City. Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor. Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed or refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor. Ambit's preclinical portfolio includes, CEP-32496, a BRAF inhibitor licensed to Teva, and a proprietary CSF1R inhibitor program. For more information, visit www.ambitbio.com.

Contacts:

Ambit Biosciences:

Alan Fuhrman

Chief Financial Officer

(858) 334-2133


Ian Stone or David Schull (Media)

Russo Partners

(619) 308-6541

(212) 845-4271

ian.stone@russopartnersllc.com

david.schull@russopartnersllc.com


Cindy McGee (Investors)

Russo Partners

(619) 308-6538

cindy.mcgee@russopartnersllc.com

SOURCE Ambit Biosciences


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES